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Abstract We present an agent-based distributed de-
cision support system for the diagnosis and progno-
sis of brain tumours developed by the HealthAgents
project. HealthAgents is a European Union funded
research project, which aims to enhance the classifica-
tion of brain tumours using such a decision support
system based on intelligent agents to securely connect
a network of clinical centres. The HealthAgents sys-
tem is implementing novel pattern recognition discrim-
ination methods, in order to analyse in vivo Magnetic
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Resonance Spectroscopy (MRS) and ex vivo/in vitro
High Resolution Magic Angle Spinning Nuclear Mag-
netic Resonance (HR-MAS) and DNA micro-array data.
HealthAgents intends not only to apply forefront
agent technology to the biomedical field, but also de-
velop theHealthAgents network, a globally distributed
information and knowledge repository for brain tumour
diagnosis and prognosis.
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1 Introduction
Brain tumours remain an important cause of morbidity
and mortality in Europe with a crude incidence rate of
8 per 100,000 inhabitants [9]. Even though it is not the
most common type of cancer overall, brain tumours ac-
count for a greater proportion of tumours in younger
age groups. This leads to them being an important
cause of cancer in young adults and children. Indeed,
brain tumours are the most common solid malignancies
in children.
While medical treatment relies on the accurate clas-
sification of a tumour, diverse studies document the dif-
ficulties faced by radiologists and oncologists in mak-
ing a non-invasive diagnosis based on traditional cra-
nial imaging only [2,13,19]. The inclusion of innovative
techniques, such as Magnetic Resonance Spectroscopy
(MRS), gives the opportunity to increase the informa-
tion available from imaging and potentially improve the
accuracy of non-invasive diagnosis. Furthermore, there
is emerging evidence that these techniques may provide
2novel biomarkers of prognosis. The use of histopathol-
ogy to classify tumours is now being augmented by
other investigations on tissue, such as molecular genet-
ics and gene expression, to improve the characterisation
of tumours and stratify them into groups of varying
prognosis.
The metabolite profiling of tissue by High Resolu-
tion Magic Angle Spinning Nuclear Magnetic Resonance
(HR-MAS) may further improve this characterisation
by probing the downstream consequences of these ge-
netic alterations. The use of ex vivo magnetic resonance
spectroscopy in the investigation of tumours gives the
potential to link these studies to in-vivo MRS and hence
the non-invasive determination of tumour tissue proper-
ties [42]. Moreover, we argue that if advanced magnetic
resonance data can be made widely available along with
clinical data, in a secure and easily accessible way, this
will significantly improve the ability of clinicians to de-
termine non-invasively the diagnosis and prognosis of
brain tumours.
The HealthAgents project [3,47] is engaged in
the development of a distributed, agent-based Deci-
sion Support System (DSS), which implements a series
of automated classifiers based on pattern recognition
methodologies for the diagnosis and prognosis of brain
tumours.
Our approach builds upon previous experiences in
biomedical informatics, particularly in image processing
and computer-aided diagnosis, where physiologic and
molecular level tumour discrimination are becoming in-
creasingly used for the early detection of tumours [24];
in machine learning for brain tumour classification us-
ing MRS [20], where high classification accuracies have
been achieved by various methodologies; and in agents,
where meaningfully codified descriptions of service ca-
pabilities have facilitated the development of protocols
for pipelining them in dynamic ways for genome anal-
ysis and medical decision support systems [11,38].
This work documents the first prototype of the DSS,
which is comprised of an agent-based architecture, with
an associated ontology, data mining techniques, and the
protocols for clinical data exchange. It is designed to al-
low users to preserve their local centre policies for shar-
ing information, whilst allowing them to benefit from
the use of a distributed data warehouse. Moreover, it
will permit the design of local classifiers targeting spe-
cific patient populations.
While the DSS provides a clinical environment us-
ing MRS, the machine learning techniques will also be
applied to ex-vivo chemometrics, micro-arrays and text
mining to correlate the transcriptomic and metabolomic
information. The use of multiple complementary data
sources will enrich the classification of brain tumours
and aid the discovery of novel prognostic markers.
All data is stored anonymously and securely through
the HealthAgents network of data marts in order to
create a distributed data warehouse. This data ware-
house contains the collection of such clinical data, that
has been properly anonymised from the original clinical
data and information acquired and stored at the various
participating European clinical centres. This incipient
network grants bona-fide access to any qualified organ-
isation in return for its contribution of clinical data to
the DSS. No personal patient information leaves the
local centres.
The rest of this paper is structured as follows. First,
we provide some background on the underlying tech-
niques for this project: determination of tumour prop-
erties, machine learning, and agents. Then we provide
the architectural specification, followed by a description
of the implementation. Finally, we conclude by review-
ing some related work and providing guidelines on our
future work.
2 Background
Nowadays the diagnosis and treatment of brain tumours
is typically based on clinical symptoms, radiological ap-
pearance and, often, a histopathological diagnosis of a
biopsy. However, treatment response of histologically or
radiologically-similar tumours can vary widely, partic-
ularly in children. MRS is a non-invasive technique for
determining the tissue biochemical composition of a tu-
mour (metabolic profile) [26]. Additionally, the genomic
profile, determined using DNA micro-arrays, facilitates
the classification of tumour grades and sub-types, which
may not be distinguished by morphologic appearance.
HealthAgents builds upon three areas of exper-
tise:
1. Determination of Tumour Properties
2. Machine Learning
3. Agents and Ontologies
2.1 Determination of Tumour Properties
Diagnosis using Magnetic Resonance Imaging (MRI) is
non-invasive, but only achieves variable accuracy de-
pending on the tumour type and grade [28]. In addition
to its intrinsic healthcare costs and stress to patients,
the stereotactic brain biopsy exhibits significant risks,
with an estimated morbidity of 2.4-3.5% [14,21] and
a death rate of 0.2-0.8% [14,15]. For tumours whose
grade may evolve over time, repeated biopsies would
3be needed to establish the current status and these may
not be clinically advisable or practical. Furthermore, tu-
mour histopathology does not reliably predict response
to treatment or outcome for all tumours and there is an
increasing emphasis on the discovery of novel biomark-
ers of tumour behaviour [23].
Hence, there is a need to improve brain tumour clas-
sification and non-invasive methods for brain tumour
diagnosis and prognosis in order to aid patient man-
agement and treatment. In the HealthAgents, three
techniques are made available to address the aforemen-
tioned requirements:
1. MRS, coupled with conventional MRI, provides me-
tabolite profiles of either a single-voxel of tumour
tissue or a grid of voxels, where a molecular im-
age of particular tumour metabolites can be ad-
ditionally produced Magnetic Resonance Spectro-
scopic Imaging (MRSI) [26,45].
2. HR-MAS is applied to biopsies in vitro in order to
provide metabolomic characterisation which is more
detailed than that available from in vivo MRS [4,
36].
3. DNA microarray analysis of biopsies can determine
tumour phenotype from gene expression profiles and
predict survival more accurately than classical his-
tology [39,41].
2.2 Machine Learning
Defined as the study of computer algorithms which im-
prove automatically through experience, machine learn-
ing can be thought as the intersection of computer sci-
ence and statistics [7]. It uses example data or past
experience to optimise a given set of performance crite-
ria. As a field of study in computer science it is some-
times referred to as “data mining,” “knowledge discov-
ery from databases,” or “advanced data analysis” [40],
and entails the solution of a series of sub-problems such
as: association, supervised learning (e.g. classification
and regression), unsupervised learning, or reinforcement
learning [1]. Hence, pattern recognition is often described
as a sub-domain of machine learning since its main fo-
cus is on supervised and unsupervised learning. Brain
tumour research provides several biological domains where
both pattern recognition and machine learning tech-
niques can be applied: chemometrics [45], metabolomics,
microarrays, genomics, proteomics, and text mining [30].
HealthAgents employs machine learning meth-
ods to provide the mathematical and computational
mechanisms to infer knowledge in a formal model from
specific brain tumour data. HealthAgents samples
brain tumour data from a training set (xi,yi), where xi
is an input pattern —a metabolic profile— and yi in-
dicates the class membership —a known pre-diagnosed
brain tumour—, with the goal of learning general mod-
els from the particular samples. Such models will min-
imise classification error on future unseen data and,
eventually, suggest a brain tumour diagnosis more ac-
curately. In order to address the solution of such clas-
sification problems, HealthAgents is developing lin-
ear and non-linear classifiers for brain tumours employ-
ing Linear Discriminant Analysis (LDA), Support Vec-
tor Machines (SVM) and Least-Squares Support Vector
Machines (LS-SVM) in combination with feature selec-
tion and feature extraction methodologies.
LDA maximises the ratio between the difference of
the projected means and the dispersion within the classes.
Ideally, this function should be optimum when the dis-
tance between means is maximum and the inside-class
dispersions are minimum. SVM are classification, non-
linear function estimation and density estimation meth-
odologies defined in the context of statistical learning
theory, kernel methods and structural risk minimisa-
tion [50]. While SVM define the optimal separating hy-
perplane between two classes with the maximal margin
in a high dimensional space by means of the kernel trick,
LS-SVM provide a reformulation of the SVM, where a
linear system is solved [44].
2.3 Agents and Ontologies
Several modern complex distributed systems are com-
posed of customisable building blocks, known as soft-
ware agents or, simply, agents. The literature enumer-
ates four important characteristics of agents [10]. First,
agents possess an internal knowledge-based state that
can be dynamically altered. Second, they have dynamic
reasoning capabilities that determine their internal be-
haviour through constraints or goals. Third, they sus-
tain a communication status that enables them to in-
teract with agents or human entities. Last, they feature
a unique identity that provides roaming and service ad-
vertising capabilities.
Software agent technology offers an increasingly pop-
ular paradigm for the design and development of certain
types of software system. This is particularly the case
for complex distributed systems, in which components
need to communicate and reason about the information
they exchange. Other approaches, such as those based
on web services, offer similar solutions but the clean and
high level software abstraction inherent in the agent ap-
proach makes agent technology an appropriate choice
for this application.
The HealthAgents scenario is one in which dis-
tributed datamarts are being built by widespread hospi-
4tal groups in various countries throughout Europe. In-
dividual hospitals do not typically encounter sufficient
cases of particular tumour types to be able to consti-
tute a sizeable training set to develop robust software-
based tumour classifiers capable of providing reliable
diagnoses and prognoses when presented with non in-
vasive imaging and spectroscopic data. A key aim of the
HealthAgents system is that, through data sharing
between hospitals across Europe, more powerful diag-
nostic and prognostic support can be facilitated. Not
only will it be possible to build local classifiers based
solely on a hospital’s own cases, but also global classi-
fiers based on aggregated appropriate cases in the dis-
tributed system. Hospitals and countries vary in their
approach to restricting the mobility of data and the sys-
tem design anticipates this variability. To build global
classifiers, classifier builder agents will typically gather
appropriate cases from across the network, but will be
able to work locally within a hospital node if the hos-
pital restricts the movement of data.
Another relatively new set of technologies, on which
we draw, is the set called “semantic web technologies”,
in which ontologies are used firstly to structure the
knowledge implicit in the data of the application, sec-
ondly as a vehicle for interoperability between software
components such as agents and finally to provide a plat-
form for reasoning over that knowledge [25].
Although there are moves towards standardisation,
different hospitals often use different schema for their
tumour case data and, in order to support interoper-
ability between the data from different hospitals and
between agents utilising that data, we have developed
several ontologies in a modular fashion. These cover the
brain tumour domain and include the relevant medical
imaging modalities, clinical information and histopath-
ological classes involved in tumour diagnosis and prog-
nosis. We are including in the ontology relevant knowl-
edge from medical experts, such as any established rela-
tionships between anatomical location and tumour type
and between clinical data and tumour type. Using this
knowledge from the ontology and information from Yel-
low Pages (YP) agents about classifier agents available
in the system, their functionality, performance charac-
teristics and reputation, agents will be able to reason
about and recommend appropriate classifiers to be used
for a particular case.
In addition to the domain ontology, which describes
what sorts of objects are referred to by components
of the system, we have developed a separate ontology,
which defines the terms to be included in the commu-
nication language used by the agents. This means the
messaging vocabulary used by agents can be expanded
without modification to the individual agents in the
system.
The use of agent technology and ontologies is not
new. Several authors have described systems in the med-
ical and bio-informatics domains and elsewhere [12,22,
31,32,33,34,38,51]. However, there are several novel as-
pects to the approach taken here, including the use
of the communication language ontology, the imple-
mentation of agent functionality through the use of a
Lightweight Coordination Calculus (LCC) [43], innova-
tions we are making to handle classifier agent perfor-
mance and reputation ranking and the integration of
an evidence-based search service. Some of these issues
are discussed more fully in the following sections.
3 Architectural Specification
Before describing the architectural specification it is in-
structive to consider a simplified high level overview of
the functionality to be achieved.
First, to begin the process, hospitals need patient
cases for which the tumour diagnosis is known from
biopsy analysis (histopathology, etc) and for which po-
tentially predictive MRI and MRS data is available.
These cases are link anonomysed and copied to the hos-
pital’s local HealthAgents datamart.
The MRS data is typically in a format dependent
on the MRS machine manufacturer and is first prepro-
cessed to a canonical form. At the request of a medical
user, and when sufficient cases are available within the
datamart, classifiers are developed to answer specific
diagnostic questions. Once trained and tested using the
appropriate cases from the distributed datamarts, the
classifier is added to the system and its existence, its
initial performance and reputation, and the profile of
its training and test data are published in the Health-
Agents YP. The ontologies for the system encompass
these descriptive labels.
A medical user, attempting to diagnose a patient
for whom MRS data is available, uses a local web based
Graphical User Interface (GUI) to initiate entry of the
case information into HealthAgents, once again in
link anonymised and canonical form. The system, via
the GUI, may be able to suggest appropriate classifiers
based on the clinical data, tumour location etc or the
user may ask, via the GUI, whether appropriate classi-
fiers are available. The GUI consults nearby YP to es-
tablish the availability of appropriate classifiers. This is
not a straightforward process. Classifiers may be appro-
priate on the basis of the tumour types between which
they can discriminate but may be less obviously suit-
able when comparing the patient profile of the case to
5be classified with the profile of the training set used to
build a particular classifier.
When performance and reputation of a classifier are
taken into account the problem of classifier selection
may become a substantial reasoning and negotiation
process and several classifiers may be capable of satis-
fying the request of the user.
In HealthAgents all potentially suitable classi-
fiers are invoked to classify the current case and the
various factors influencing classifier choice are used to
rank the results unless the user makes a specific over-
riding choice. The classifiers may be located at classi-
fier nodes anywhere on the HealthAgents network, in
which case the data to be classified may be sent from the
hospital to the remote classifier nodes for classification.
If the hospital does not allow data to leave the local
node, classifiers may be run locally. Results from the
different classifiers are gathered, ranked and returned
to the user via the GUI to support the user’s decision
making processes. Classifier results are also recorded in
the system so that, if and when a confirmed diagnosis is
available for a case, an estimate of the “dynamic” per-
formance and reputation of classifiers can be updated.
In addition to the classification processes described
above, theHealthAgents system provides an Evidence-
based Search Service (EbSS) which seeks, in a context
sensitive way, papers from the medical literature to as-
sist the medical user in the current task. The search
service has a manual mode in which the users indicate
the topics for which supporting material is required but
an automatic search mode may also be triggered by the
classification processes being undertaken and the result-
ing literature made available to the user if desired.
This simplified overview of functionality suggests
the need for at least the following agents:
– Database agents to handle input and output of cases
to and from the hospital datamarts
– Preprocessing agents to convert imaging data to canon-
ical form
– GUI interface agents to handle interaction with med-
ical users at hospital nodes
– YP agents to keep track of resources in the system
including the location of case data, classifiers and
their profiles, performance and reputations.
– Classifier builder agents to (help to) gather appro-
priate cases and build, train and test classifier agents
– Classifier agents to provide tumour classifications
based on case data
– Petitioner agents to invoke appropriate classifiers
and gather and rank results
– EbSS agents to provide the context sensitive infor-
mation searching
Fig. 1 The HealthAgents Multi-layer Framework
A multi-layer agent framework has been built in or-
der to provide seamless integration of the new function-
alities into HealthAgents with minimum program-
ming effort, as well as to support information extrac-
tion and analysis in a timely fashion. By deliberately
abstracting all specific agent functionality from the in-
terface, this framework enables platform independence.
The framework, as depicted in Figure 1, is composed of
the following layers:
Database Mapping The database-mapping layer is used
to map relational database schemas to the Health-
Agents ontological schema.
Application Programming Interface (API) The program-
matic API layer abstracts the underlying database
interaction from the agent architecture.
Business Methods The business methods layer contrib-
utes the main functionality of the agent such as new
case classification, data retrieval from a datamart
etc.
Security and Trust The security and trust layer is a
crucial system component due to the sensitivity of
the data. Its functionalities are access control, data
marshalling, tracking of on-going data, and the eval-
uation of reputation and trust of agents.
Agent The agent layer is in charge of all the commu-
nications and allows their abstraction from the rest
of the system to allow flexibility in the underlying
framework. Thus, we can use any agent development
platform by modifying this layer only.
Semantic The semantic description contains the descrip-
tion of what the agent holds and what it is able to
do.
6Listing 1 The Interaction Model for the YP Agent
// Here YPID i s a ye l lowpages i d e n t i f i e r
// and AID i s an agent i d e n t i f i e r
a ( ye l lowpages ,YPID) : :
(
(
// Check i f someone i s r e g i s t e r i n g with us
r e g i s t e rReque s t ( A b i l i t i e s ) <= a( r e g i s t r an t ,AID)
<− r e g i s t e r (AID , Ab i l i t i e s ) // then
)
or
(
// Check i f someone i s searching us
searchRequest ( Ab i l i t i e s ) <= a( searcher ,AID)
<− search ( Ab i l i t i e s , Resu l t s ) then
searchResponse ( Resu l t s ) => a ( searcher ,AID)
)
// . . .
)
The API at the agent layer consists of the basic
messaging interface that queues incoming messages and
currently takes them off the queue one-by-one to pro-
cess them. The messages are automatically tagged with
conversation identifiers to relate outgoing messages with
their responses. What constitutes a conflicting message
very much depends on the agent’s functionality and
such situations are not explicitly handled in the mes-
saging interface.
That said, formal agent messaging definitions can be
used to specify precisely what messages an agent should
be expecting in the course of its execution. By providing
an executable workflow definition we can simply invoke
a workflow and the agent will behave in a determined
way, allowing the agent’s behaviour to be easily altered
or updated by those with the necessary authorisation.
Listing 1 shows part of the interaction model for the
YP agent, encoded in LCC:
Communications within the HealthAgents net-
work are governed by two complementary ontologies:
1. The communication ontology defines an agent lan-
guage, the HealthAgents Language (HAL), con-
taining message primitives that support theHealth-
Agents architecture; for example, there are defi-
nitions for registration and deregistration messages
received by YP agents that specify what data is
required in that message. This language has been
defined using the Prote´ge´ ontology editor [17] as a
Web Ontology Language (OWL) [37] ontology. In
the agents, a Turtle [5] representation is used for
conciseness.
The ontology has been mapped to Foundation of In-
telligent Physical Agents (FIPA) performatives [27]
should the underlying agent layer support such mes-
sages.
Listing 2 YP Registration for a Classifier Agent
@pre f ix h a l : <ht tp : //www. hea l thagen ts . net/
HAAgentCommunicationLanguage . owl#> .
@pre f ix r d f : <ht tp : //www.w3 . org /1999/02/22− rdf−
syntax−ns#> .
hal :messageContent
rd f : t y pe ha l :Ye l l owPage s Reg i s t e r Reque s t ;
ha l :has−agent−to−r e g i s t e r h a l : o b j e c t 1 ;
ha l :has−a b i l i t i e s ha l : o b j e c t 2 .
ha l : o b j e c t 2
ha l :has−c l a s s−name ”net . h e a l thagen t s . agent .
RDFCollection” ;
ha l :has−c o l l e c t i o n−item ha l : ob j e c t1455484972 ;
ha l :has−c o l l e c t i o n−item ha l : ob j e c t1638383633 .
ha l : ob j e c t1638383633
hal :has−a b i l i t y ha l :has−name ;
ha l :has−c l a s s−name ”net . h e a l thagen t s . agent .
Spe c i f i cAgen tAb i l i t y ” ;
ha l :has−ab i l i t y−s p e c i f i c a t i o n ”5
agmmas mrs l e se lda 001 ” .
ha l : ob j e c t1455484972
hal :has−c l a s s−name ”net . h e a l thagen t s . agent .
Spe c i f i cAgen tAb i l i t y ” ;
ha l :has−ab i l i t y−s p e c i f i c a t i o n h a l : C l a s s i f i e r ;
ha l :has−a b i l i t y ha l :has−type .
ha l : o b j e c t 1
ha l :has−c l a s s−name ”net . h e a l thagen t s . agent .
j ade . JadeAgen t Id en t i f i e r ” ;
ha l :has−jade−agent−platform−addre ss <ht tp : //
pas iphae :1633 / acc> ;
ha l :has−jade−agent−id−name ” Cla s s i f i e r@192
. 1 6 8 . 2 . 1 1 :1099 /JADE” ;
ha l :has−jade−agent−platform−addre ss <ht tp : //
pas iphae :7778 / acc> ;
ha l :has−jade−agent−platform−addre ss <ht tp : //
pas iphae :1632 / acc> .
2. The domain ontology defines concepts and relations
relating to brain tumour diagnosis. The ontology
is used to facilitate interoperability between agents
and disparate data resources, and also to provide
support for agent based learning and reasoning pro-
cesses.
Listing 2 shows an example of the use of HAL for
the process of YP Registration for a classifier agent.
In summary, whilst focusing on a specific knowl-
edge domain –brain tumour diagnosis and prognosis–,
HealthAgents is creating a generic intelligent agent
communication architecture to securely connect user
sites with a distributed database and provide appro-
priate support for applications built thereon.
Moreover, the architecture specification is intended
to support the building of a completely distributed repos-
itory of local databases. An overview of the data flow
is shown in Fig 2.
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Fig. 3 The Multi-Node HealthAgents Architectural Imple-
mentation
4 Implementation
Conceived as an open-source platform, the Health-
Agents DSS is implemented using the Jade agent de-
velopment environment [6], Java, Ant and D2RQ [8],
and supported under Windows and Linux platforms,
and intended to be distributed into four different types
of computing nodes with at least one active agent, as
depicted in Figure 3.
Pre-processing node. Involves not only the conver-
sion of time-domain MRS data into frequency-domain
data but also the increase of its signal/noise ratio. It
requires the application of both a Lorentzian apodis-
ation and a Fast Fourier Transform on the metabolic
profile.
Classifier node. Implements classification functions and
data projection based on the LDA latent space, im-
plemented as classification agents in the Health-
Agents network. These agents provide not only
support to the decision-making process during the
diagnosis of new patients, but also seamless access
to the results at the GUI to the classification model.
Database node. Includes an ontological mapping be-
tween the relational database and theHealthAgents
ontology. By designing the agent system to utilise
semantic web querying mechanisms via D2RQ, we
assure the maximum flexibility for integration of dif-
ferent functionality as the network gets larger, as
well as providing the ability to run more advanced
reasoning over the data.
EbSS node. Provides contextualised searches, classi-
fication oriented searches, and generates an on-line
literature search.
Client node. Furnishes the HealthAgents GUI to
upload the raw data and visualise the result of the
classification. This agent manages the user interac-
tion with the MRS raw data, and is crucial to assure
patient confidentiality through its anonimisation ca-
pabilities.
Currently, the HealthAgents DSS furnishes clas-
sifiers for aggressive tumours (glioblastomas and metas-
tasis), benign meningiomas and a low-glial mixture (as-
trocytomas grade II, oligodendrogliomas and oligoas-
trocytoma), and its functionality is primarily based on
the Interpret DSS system [49].
The system will also ensure that new versions of the
classifiers and their models are made available. These
updates are based on any newly validated data entering
the system, used to adapt and improve the behaviour of
the classifiers with respect to the constantly changing
evidence in the field. In addition, updates incorporate
any feedback from clinical users of the system. This
type of feedback is considered the most useful infor-
mation for the improvement of the DSS. A reputation
subsystem using contextual evidence such as user choice
of classifiers, clinician feedback and background evalu-
ations of the classifiers will eventually provide quality
information and statistics on the classifiers.
4.1 DSS Operation
Firstly, in the HealthAgents DSS operation to up-
load the MRS raw data to the system, is in situ anonymi-
sation employing the HealthAgents GUI. This is a
critical process, because HealthAgents ensures that
no personal patient information leaves a clinical cen-
tre. This applies to both clinical data records and data
files such as MRI and MRS signals (raw data). Patient
identifiable information is removed from these data files
within the collecting hospital by a process of anonymi-
sation. This user interaction is illustrated in Figure 4 (a).
Secondly, once the data is completely anonymised,
the MRS raw data is sent from the client to the pre-
processing agent. The pre-processing agent transforms
the rawMRS data file from the scanner into theHealth-
Agents data format, invokes the classifiers and sends
the results back to the client.
The classification of a case is done in a specialised
node (or nodes) where the trained classifiers reside.
This classification is undoubtedly the cornerstone in
8the HealthAgents functionality as the basic database
agent manages the interactions with theHealthAgents
network which groups the different clinical centres (data
marts) where classifiers are trained. This is depicted in
Figure 4 (b). It is important to note that the accuracy
of the classifiers depends heavily on the number of cases
and therefore on the size of the HealthAgents net-
work. The prototype currently contains a few hundred
cases, and new cases will be acquired and incorporated
from clinical centres in Spain and the United Kingdom
within the following months.
Thirdly, the GUI agent collects the result of the pre-
processing module in order to plot the spectra, the MRI
(if any) and the classification of the current case in the
latent space as shown in Figure 4 (c). While the visuali-
sation is essentially based on previous experiences [45],
the agent and web-based capabilities will enable the
GUI a seamless operation across networks.
Fourthly, the suggested case classification along with
the MRI raw data is presented as local visualisation
queries, since personal data never goes out of a clini-
cal centre in order to meticulously preserve the patient
identity.
The overall functioning is presented in Figure 5.
5 Evaluation
The goal of this initial empirical evaluation is twofold:
to evaluate the distributed agent infrastructure and to
obtain the estimation of the true accuracy (or true er-
ror) of an inferred classifier by applying it to real data.
In order to evaluate HealthAgents and its afore-
mentioned functionalities, we have been deployed the
system using the following software:
– Java 1.4.2
– Java 2 Runtime Environment, Standard Edition
(build 1.4.2 06-b03)
– Java HotSpot Client VM (build 1.4.2 06-b03, mixed
mode)
– Ant 1.7.0
– Jade 3.4
– D2RQ 0.5
The agent architecture has been deployed into the
following nodes:
Pre-processing node
Server Dell SC1425
Xeon 3.2Ghz/2MB 300 Mhz FSB processor
1GB Single Rank DDR2 Memory (2x512MB)
OS: Red Hat Enterprise Linux, x86 64 GNU/Linux
Classifier node
Server Dell PowerEdge 1850
(a) Anonymisation
(b) Classification
(c) Visualisation
Fig. 4 The HealthAgents Graphical User Interface (GUI). (a)
Anonymisation process of MRS data. (b) Classification. The clas-
sification results and their communication messages are combined
into a single view. (c) Visualisation. The case classification within
the latent space is presented in the upper left part of the screen.
Different types of tumours are presented as tick-in boxes in the
bottom left portion of the screen. The MRS is presented on the
right hand panel along with the MRI of the case. General infor-
mative fields on the cases are enlisted in the bottom and top left
lines.
9Fig. 5 The Operation of the HealthAgents DSS (functional
view)
2x Xeon 3.2Ghz/2MB 300 Mhz FSB processors
2GB Single Rank DDR2 Memory (2x1GB)
OS: Red Hat Enterprise Linux, x86 64 GNU/Linux
GUI Agent
Workstation, Dell Latitude D610
Intel pentium M 2Ghz processor
1GB Single Rank memory
OS: Microsoft Windows XP Professional [v 5.1]
From a systems infrastructure standpoint, Figure 6
illustrates the system monitoring in HealthAgents.
Figure 6 (a) presents a time chart with the message se-
quence for the connection between the GUI agent and
two classifier agents, using a series of service requests
through YP agent. Figure 6 (b) shows the monitor-
ing of the system using the HealthAgents Process
Manager. Finally, the Listing 3 presents the Health-
Agents initialisation log for the overall platform.
As far as the classification is concerned, we have de-
ployed a LDA classifier to perform a high-level discrim-
ination comprising three tumour superclasses: gmme
containing the glioblastoma multiforme (gm) and me-
tastasis (me) aggressive tumour classes; mm for menin-
giomas; and a2odoa comprising a low-glial mixture of
astrocytomas grade II (a2), oligodendrogliomas (od),
and oligoastrocytoma (oa).
We have employed single-voxel MRS data on the
Interpret database [29], executed on a single node in-
stance, to perform descriptive discrimination of the afore-
mentioned three tumour types. We have employed a
discriminative model adjusted using terms from Short
Time Echo (STE) and Long Time Echo (LTE) MRS
data, and the terms in the three types were matched
to single spectral points in the [0.5..4.1]ppm range. A
stepwise procedure based on the leaving-one-out evalu-
Listing 3 Log for the HealthAgents Platform Initialisation
(28-may-2007)
[ java ] 28−may−2007 12 : 4 6 : 3 2 jade . core . Runtime
beg inConta iner
[ java ] INFO: −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
[ java ] This i s JADE3.4 − r e v i s i o n 5874 o f
2006/03/09 14 : 1 3 : 1 1
[ java ] downloaded in Open Source , under LGPL
r e s t r i c t i o n s ,
[ java ] at h t tp : // jade . t i l a b . com/
[ java ] −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
[ java ] 28−may−2007 12 : 4 6 : 3 3 jade . core . BaseServ ice
i n i t
[ java ] INFO: Se rv i c e jade . core . management .
AgentManagement i n i t i a l i z e d
[ java ] 28−may−2007 12 : 4 6 : 3 3 jade . core . BaseServ ice
i n i t
[ java ] INFO: Se rv i c e jade . core . messaging .
Messaging i n i t i a l i z e d
[ java ] 28−may−2007 12 : 4 6 : 3 3 jade . core . BaseServ ice
i n i t
[ java ] INFO: Se rv i c e jade . core . mob i l i ty .
AgentMobi l i ty i n i t i a l i z e d
[ java ] 28−may−2007 12 : 4 6 : 3 3 jade . core . BaseServ ice
i n i t
[ java ] INFO: Se rv i c e jade . core . event . No t i f i c a t i o n
i n i t i a l i z e d
[ java ] 28−may−2007 12 : 4 6 : 3 3 jade . core . messaging .
Messag ingServ ice boot
[ java ] INFO: MTP addr e s s e s :
[ java ] h t tp : // deve l : 7778/ acc
[ java ] 28−may−2007 12 : 4 6 : 3 3 jade . core .
AgentContainerImpl j o i nP l a t f orm
[ java ] INFO: −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
[ java ] Agent c on ta in e r Main−Container@JADE−IMTP:
// deve l i s ready .
[ java ] −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
[ java ] − Welcome to HealthAgents
[ java ] − I n i t i a l Action c a l l e d .
[ java ] − Reg i s t e r with Direc tory F a c i l i t a t o r . . .
[ java ] − Reg i s t e r with Direc tory F a c i l i t a t o r . . .
[ java ] − Messaging Se rv i c e I n i t i a l i s e d with agent
rpHAJMSA
[ java ] − Agent se t to net . h e a l thagent s . agent . j ade
. JadeMessagingServiceAgent@7c138c63
Superclass Classes Nsamples Total samples
gmme gm 74 102
me 28
mm mm 51 51
a2odoa a2 20 29
od 5
oa 4
TOTAL 182 182
Table 1 Brain Tumour Sampling
ation of an LDA classifier was used to obtain the subset
of points more discriminant for the multi-class task. A
summary of the sampling is presented in Table 1 with
further details described in [48].
We have observed that the combined model, LTE
and STE, has obtained a good accuracy (> 90%) in
the leaving-one-out evaluation, and a marginal improve-
ment compared with models based on STE or LTE
alone.
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(a) GUI - Classifier Connection
(b) The HealthAgents Process Manager
Fig. 6 System Monitoring in HealthAgents. (a) Sequence of
service requests for the connection between the GUI and the clas-
sifier agents using the YP agents (b) The operation of the system
can be monitored with the HealthAgents Process Manager
6 Related Work
Machine learning surveys have summarised tumour clas-
sification techniques based on pattern recognition and
clustering methods [20]. Eight of these studies were ap-
plied to brain tumour discrimination from normal tis-
sue and other central nervous system diseases. All of
them were based on LDA or artificial neural networks
and were applied over relative metabolites and prin-
cipal component transformations. Furthermore, auto-
matic brain tumour grading and image segmentation
techniques, based on computational intelligence tech-
niques, have successfully been applied to different case
sets in the past five years [16,18,35].
There are a handful of projects which implement
computer-assisted evidence-based brain tumour diag-
nosis using MRS. The Interpret project produced a
centralised decision support system for single centres
with classification based on histopathological diagno-
sis [45]. Interpret has successfully been used to dis-
criminate among low-grade meningiomas, high-grade
tumours (glioblastomas and metastases), and low-grade
glial tumours. The eTUMOUR project incorporatesMRS
biochemical profiles from single voxel and metabolic
spatial distribution by chemical shift imaging [46].
While the functionality of the first prototype is based
on the single-voxel version of Interpret [45], Health-
Agents expands the original Interpret capabilities with
a distributed multi-centre agent architecture, an in-vivo
classification method with negotiation, an additional
number of cases located in different centres across Eu-
rope, and a web-based user interface.
7 Concluding Remarks
In vivo MRS combined with ex vivo/in vitro HR-MAS
and gene expression promises to improve the classi-
fication of brain tumours and yield novel biomarkers
for prognosis. Considerable amounts of highly complex
data are required to build reliable specific tumour clas-
sifiers and it is a challenge to collect and manage this
data. HealthAgents has started to address this prob-
lem by building a distributed system of databases cen-
tred on the users and managed by agents. As a result,
HealthAgents proposes a unique blend of state-of-
the-art technologies to develop novel clinical tools for
the diagnosis, management and understanding of brain
tumours.
HealthAgents extends the traditional scope of
machine learning classification by providing a distributed
agent-based approach, which enables the system to be
re-trained using aggregated sources while preserving se-
curity and patient privacy. Future work will include
the application of LS-SVM to improve the combined
approach and to characterise its behaviour in pairwise
classifications. Indeed, HealthAgents is also devel-
oping probabilistic mixture models and hierarchical ag-
glomerative clustering for density estimation of hetero-
geneous brain tumour types and gene co-expression pro-
files.
The most promising and ambitious development in
machine learning for the project is to provide a retrain-
ing system for the classifiers deployed in the network. It
is expected to enhance the accuracy of the classifiers; to
assist wisely in the compilation of additional biomedical
data from affiliated clinical centres; and, above all, to
improve the data sets leading to a more comprehensive
and accurate tumour discrimination.
We argue that the HealthAgents DSS furnishes
a completely new approach to brain tumour diagnosis.
Since inferences from local predictions are based on lim-
ited amounts of data, they may well conflict with one
another. Reasoned argument among intelligent agents,
in a multi-agent system, will produce a consensus based
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on data available from a large range of databases hence
improving reliability and accuracy. Additionally,Health-
Agents aims to provide new concepts relating to the
brain tumour domain, while introducing additional ele-
ments relating to analytic techniques, such as MRS, in
the context of the project.
HealthAgents intends not only to apply agent
technology to the biomedical field in a multi-disciplinary
fashion, but also to develop the first distributed repos-
itory for brain tumour diagnosis, leading eventually to
the formation of a special interest data grid, theHealth-
Agents network.
In this work we have presented the first release of the
HealthAgents decision support system. Although still
in development, the experience gained from production
of an initial prototype strongly suggests that a system
based on distributed intelligent agents can produce an
innovative software system to help in the fight against
one of the most pernicious diseases of our time: cancer.
List of Acronyms
API Application Programming Interface
DSS Decision Support System
EbSS Evidence-based Search Service
FIPA Foundation of Intelligent Physical Agents
GUI Graphical User Interface
HAL HealthAgents Language
HR-MAS High Resolution Magic Angle Spinning Nuclear
Magnetic Resonance
LCC Lightweight Coordination Calculus
LDA Linear Discriminant Analysis
LS-SVM Least-Squares Support Vector Machines
LTE Long Time Echo
MRI Magnetic Resonance Imaging
MRS Magnetic Resonance Spectroscopy
MRSI Magnetic Resonance Spectroscopic Imaging
OWL Web Ontology Language
STE Short Time Echo
SVM Support Vector Machines
YP Yellow Pages
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